Product Revenue, Net was ARS Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $72.19M of $84.28M (86%).
| Product and Service | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Product Revenue, Net | — | $7.26M | $72.19M |
| Revenue Under Collaboration Agreements | $30.00K | $81.53M | $9.72M |
| Revenue Under Supply Agreements | — | $365.00K | $2.37M |
| Total | $30.00K | $89.15M | $84.28M |
ARS Pharmaceuticals brought in $84.28M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 5.5% from $89.15M in fiscal 2024. Product Revenue, Net was the largest at $72.19M (85.7%), ahead of Revenue Under Collaboration Agreements at $9.72M (11.5%) and Revenue Under Supply Agreements at $2.37M (2.8%).
Compared with fiscal 2024, Product Revenue, Net grew fastest, up 895.1% to $72.19M, while Revenue Under Collaboration Agreements fell the most, down 88.1% to $9.72M.
ARS Pharmaceuticals began breaking out Product Revenue, Net in fiscal 2024 and Revenue Under Supply Agreements in fiscal 2024.
United States was ARS Pharmaceuticals’s largest region in fiscal 2025, bringing in $72.19M of $84.28M (86%).
| Geography | FY 2024 | FY 2025 |
|---|---|---|
| Rest Of World | $81.89M | $12.09M |
| United States | $7.26M | $72.19M |
| Total | $89.15M | $84.28M |
ARS Pharmaceuticals brought in $84.28M from its two regions in fiscal 2025, the year ended December 31, 2025. That was down 5.5% from $89.15M in fiscal 2024. United States was the largest at $72.19M (85.7%), ahead of Rest Of World at $12.09M (14.3%).
Compared with fiscal 2024, United States grew 895.1% to $72.19M, while Rest Of World fell 85.2% to $12.09M.
ARS Pharmaceuticals (SPRY) reports its revenue by product and service and by geography. In fiscal 2025, Product Revenue, Net was its largest product and service line, bringing in $72.19M (85.7% of the total), followed by Revenue Under Collaboration Agreements at $9.72M (11.5%).
Product Revenue, Net was ARS Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $72.19M, or 85.7% of the $84.28M total across its three product and service lines.
United States was ARS Pharmaceuticals' largest region in fiscal 2025, bringing in $72.19M, or 85.7% of the $84.28M total across its two regions.
Among ARS Pharmaceuticals' product and service lines that make up at least 2% of revenue, Product Revenue, Net grew fastest in fiscal 2025, up 895.1% from $7.26M to $72.19M.
Every figure comes from ARS Pharmaceuticals' annual financial filings, as reported. Each line keeps the name ARS Pharmaceuticals gives it, and years follow its fiscal calendar.
ARS Pharmaceuticals' revenue by product and service goes back to fiscal 2023, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.